What is the accuracy of different combinations of ultrasound imaging and blood tests to diagnose ovarian cancer in women before and after the menopause?
Wednesday, November 9, 2022 (Source: Cochrane News and Events)
Source: Cochrane News and Events - November 9, 2022 Category: Information Technology Authors: Paolo Rosati Source Type: news
Surveillance Feasible for Women Deferring Prophylactic Salpingo-Oophorectomy
WEDNESDAY, Nov. 2, 2022 -- For women deferring risk-reducing bilateral salpingo-oophorectomy (RRSO), surveillance for ovarian cancer (OC) is feasible, yields a high complete cytoreduction rate, and is cost-saving, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 2, 2022 Category: Pharmaceuticals Source Type: news
Ovarian cancer surveillance an option for women with BRCA variants
Ovarian cancer surveillance is a viable option for women with BRCA gene variant...Read more on AuntMinnie.comRelated Reading:
TVUS reliable as first-line test for endometrial cancer staging
Transvaginal ultrasound may not be needed to check IUD position
Out with the old, in with new for uterine bleeding terms, TVUS
Ultrasound on par with MRI to measure myometrial invasion depth
Ultrasound misses endometrial cancer in Black women (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 2, 2022 Category: Radiology Source Type: news
The ultimate detour: Breast cancer brings battle to home front
There are an estimated 18.2 million cancer survivors in the U.S. and, among those, the most common are female breast cancer survivors — making up 22%.
“What I think people don’t fully understand is breast cancer is different, especially in a woman because it affects all of the parts of her that make her feel like a woman,” said Lauren Roberts, executive director of the Forge Survivorship Center in Birmingham. “Her hair, her eyebrows, her eyelashes, her breasts, a lot of times her ovaries.… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - October 31, 2022 Category: American Health Authors: Laurel Thrailkill Source Type: news
Pathfinder 2022: faster, further and fairer
This report shows that although there have been significant improvements over the years for women with ovarian cancer, not enough progress has been made in diagnosis, awareness, treatment and support. It reveals that if diagnosis was faster, further support was available and access to treatment was fairer, there could be potential for more women to survive, live well with ovarian cancer and be supported from diagnosis and throughout treatment. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - October 24, 2022 Category: Consumer Health News Source Type: news
Ovarian cancer achieving better outcomes
This report shows that although there have been significant improvements over the years for women with ovarian cancer, not enough progress has been made in diagnosis, awareness, treatment and support. (Source: NHS Networks)
Source: NHS Networks - October 24, 2022 Category: UK Health Source Type: news
New Findings on Rare Mucinous Ovarian Cancer May Change Tx New Findings on Rare Mucinous Ovarian Cancer May Change Tx
A global study of the microscopic patterns of cell growth in samples taken from women with this rare form of ovarian cancer may lead to treatment changes for some.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 21, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
TVUS reliable as first-line test for endometrial cancer staging
Transvaginal ultrasound (TVUS) may not be as accurate as MRI when it comes t...Read more on AuntMinnie.comRelated Reading:
Transvaginal ultrasound may not be needed to check IUD position
4D ultrasound shows fetuses reacting to taste, smell
Elastography shows women with COVID history have stiffer placentas
Deep learning measures up to experts for ovarian ultrasound
Ultrasound links abnormal findings in infants to neurobehavioral issues (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 21, 2022 Category: Radiology Source Type: news
GPs need support and rapid diagnostics to pick up ovarian cancer early
GPs need better access to diagnostic tests and more support to boost early diagnosis of ovarian cancer, a report warns. (Source: GP Online News)
Source: GP Online News - October 19, 2022 Category: Primary Care Tags: Clinical News Source Type: news
Scientists develop more accurate predictive test for cervical cancer
Test created by UCL and Innsbruck University also detects DNA markers for breast, womb and ovarian cancerScientists have developed a more accurate test for cell changes that can lead to cervical cancer.The revolutionary test can also pick up DNA markers for some other common cancers, meaning that it could in future be used as a predictive test for breast, womb, cervical and ovarian cancer.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - October 19, 2022 Category: Science Authors: Andrew Gregory Health editor Tags: Cervical cancer Cancer research Women's health Medical research UCL (University College London) UK news Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche records solid results for the first nine months of 2022
Group salesup 2%[1] at constant exchange rates (CER) and 1% in Swiss francs; as expected, significantly lower COVID-19-related sales in both divisions in the third quarterSales in the Pharmaceuticals Divisionat the previous year ’s level with significantly lower sales of COVID-19-related products (Ronapreve and Actemra/RoActemra) and losses to biosimilars, offset by strong growth of newer medicinesSales in the Diagnostics Divisionrise 6%; base business remains strong; as expected, demand for COVID-19 tests sharply down in third quarterHighlights in the third quarter:EU approval forVabysmo (severe eye diseases)US approval...
Source: Roche Investor Update - October 18, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche records solid results for the first nine months of 2022
Basel, 18 October 2022Group salesup 2%1 at constant exchange rates (CER) and 1% in Swiss francs; as expected, significantly lower COVID-19-related sales in both divisions in the third quarterSales in the Pharmaceuticals Divisionat the previous year ’s level with significantly lower sales of COVID-19-related products (Ronapreve and Actemra/RoActemra) and losses to biosimilars, offset by strong growth of newer medicinesSales in the Diagnostics Divisionrise 6%; base business remains strong; as expected, demand for COVID-19 tests sharply down in third quarterHighlights in the third quarter:EU approval forVabysmo (severe eye ...
Source: Roche Media News - October 18, 2022 Category: Pharmaceuticals Source Type: news
Latest Mesothelioma T-Cell Clinical Trial Moves to Phase II
The most recent T-cell therapy aimed at mesothelioma cancer has advanced to phase II of the clinical trial process, with researchers exploring its effectiveness when combined with an already approved immunotherapy duet.
Investigators are studying the synergistic effect of gavocabtagene autoleucel (gavo-cel) when used with the combination of Opdivo and Yervoy, which was approved by the U.S. Food and Drug Administration in 2020 to treat mesothelioma.
Its earlier phase I results, when used alone, were impressive – 93% of patients experienced tumor regression – raising hopes for a much-needed advancement in mesotheli...
Source: Asbestos and Mesothelioma News - October 17, 2022 Category: Environmental Health Authors: Lynette Zilio Source Type: news
The Race to Make a Vaccine for Breast Cancer
When Karen Lynch was diagnosed with breast cancer at age 44, it was a shock, but not a complete surprise. “My family history is just riddled with cancer; my father had prostate cancer and died from stomach and esophageal cancer, and his five sisters passed from breast cancer,” she says. “My mother died from pancreatic cancer.” It was 1996, and genetic testing was not as routine as it is now, so it wasn’t until nine years after her diagnosis and treatment with lumpectomy and radiation that Lynch learned she carried the BRCA1 mutation, which increases her risk of breast cancer and ovarian cancer...
Source: TIME: Health - October 6, 2022 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Cancer feature Frontiers of Medicine 2022 healthscienceclimate sponsorshipblock Source Type: news
Orphan Drug Designation Given to New Mesothelioma CAR T-Cell Therapy
In early 2023, the world-class Hospital of the University of Pennsylvania will open a groundbreaking clinical trial for mesothelioma patients utilizing a next-generation immunotherapy with a novel delivery platform.
The U.S. Food and Drug Administration cleared the path in September by granting orphan drug designation for SynKIR-110, a CAR T-cell therapy designed to target solid tumors expressing a specific protein typically found in mesothelioma cancer.
By granting the orphan drug designation, the FDA can provide financial incentives such as tax credits for clinical trials and seven years of market exclusivity. It i...
Source: Asbestos and Mesothelioma News - October 5, 2022 Category: Environmental Health Authors: Fran Mannino Source Type: news
